Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

数据显示，Opdivo联合Yervoy治疗显著延长患者的总生存期（OS），达到试验的主要临床终点。Opdivo加Yervoy联合疗法组患者的中位OS为23.7个月（95% CI：18.8–29.4），而活性对照药物组患者的中位OS为20.6个月（95% CI：17.5–22.5），风险比为0.79（0.65–0.96；p=0.018）。总生存期获益在各患者亚组中大致一致。

Phase 2 data have shown promising efficacy with nivolumab combined with ipilimumab in this patient population, and data already published from the ongoing, phase 3 CheckMate 8HW trial show ...

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

A breakthrough cancer treatment plan could be a "cure" for a death sentence form of the disease. An experimental new ...

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...

For nearly 20 years, mesothelioma treatment options were limited to a single regimen: pemetrexed with a platinum agent. Now, ...

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.